



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTS**

Attorney Docket No.  
**R0148B-REG**

Serial No.  
**10/731,581**

Applicants  
**Robert Than Hendricks, et al.**

Filing Date  
**December 9, 2003**

Group  
**not known**

**U.S. PATENT DOCUMENTS**

Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date
PL	A-1	3,998,807	21-Dec-1976	John G. Moffatt		
PL	A-2	4,957,924	18-Sep-1990	Lilia M. Beauchamp		
PL	A-3	5,216,142	01-Jun-1993	Horrobin, et al.		
PL	A-4	6,184,376	06-Feb-2001	Leanna, et al.		

**FOREIGN PATENT DOCUMENTS**

	Ref.#	Document #	Date	Country, Assignee	Translation	
					Yes	No
IC	B-1	WO 02/100415 A2	19-Dec-2002	F. Hoffmann-La Roche AG		
1	B-2	WO 01/45509 A1	28-Jun-2001	ICN Pharmaceuticals		
	B-3	WO 01/68034 A2	20-Sep-2001	ICN Pharmaceuticals		
	B-4	WO 00/23454 A11	27-Apr-2000	Schering Corp.		
	B-5	WO 94/22887 A1	13-Oct-1994	Norsk Hydro A.S.		
	B-6	WO 94/24134 A1	27-Oct-1994	Hoechst AG		
	B-7	WO 93/07163 A1	15-Apr-1993	Norsk Hydro A.S.		
	B-8	EP 0 375 329 B1	27-Jun-1990	The Wellcome Foundation Ltd.		
↓	B-9	EP 0 343 133 b1	23-Nov-1989	Medivir Aktiebolag		
PL	B-10	WO 98/16186 A2	23-Apr-1998	ICN Pharmaceuticals		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANTS</b>		Attorney Docket No. <b>R0148B-REG</b>	Serial No. <b>107731,581</b>
		Applicants <b>Robert Than Hendricks, et al.</b>	
		Filing Date <b>December 9, 2003</b>	Group <b>not known</b>

  

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
R	C1	BALIMANE, et al., "Direct Evidence for Peptide Transporter (PEPT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir," Biochemical and Biophysical Research Communications, (1998) pp. 246-251, vol. 250, Article No. RC989298	
	C2	BEAUCHAMP, et al., "Amino Acid Ester Prodrugs of Acyclovir," Antiviral Chemistry & Chemotherapy, (1992), pp. 157-164, 3(3)	
	C3	CHAMBERLAIN, et al., "2'-Ester Prodrugs of the Varicella-Zoster Antiviral Agent, 6-Methoxypurine Arabinoside," Antiviral Chemistry & Chemotherapy, (1992), pp. 371-378, 3(6)	
	C4	HARDEN, et al., "Prodrugs of the Selective Antiherpovirus Agent 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties," J. Med. Chem., (1989), pp 1738-1743, 32	
	C5	HODGE, et al., "Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpovirus Agent BRL 39123 [9-4(-Hydroxy-3-Hydroxymethylbut-1-yl)Guanine; Penciclovir]," Antimicrobial Agents and Chemotherapy, (1989), pp. 1765-1773, 33(10).	
	C6	JONES, et al. "Di- and Triester Prodrugs of the Varicella-Zoster Antiviral Agent 6-Methoxypurine Arabinoside," J. Med. Chem., (1992), pp. 56-63, 35.	
	C7	KIM, et al., "Synthesis and Evaluation of 2-Amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine Mono- and Diesters as Potential Prodrugs of Ganciclovir," J. Med. Chem., (1999), pp. 324-328, 42.	
	C8	NIELSEN, et al., "Human Peptide Transporters: Therapeutic Applications," Expert Opinion, Ther. Patents (2002), pp. 1329-1350, 12(9), Ashley Publications	
V	C9	PUE, et al., "Pharmacokinetics of Famciclovir in Man," Antiviral Chemistry & Chemotherapy, (1993), pp. 47-55, 4, Suppl. 1	
R	C10	RUBIO-ALIAGA, et al., "Mammalian Peptide Transporters as Targets for Drug Delivery," Trends in Pharmacological Sciences, (2002), pp. 434-440, 23(9)	

  

EXAMINER 	DATE CONSIDERED <b>8-2-06</b>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/731,581
Filing Date	December 9, 2003
First Named Inventor	Robert Than Hendricks
Art Unit	1632
Examiner Name	To be assigned
Attorney Docket Number	R0148B-REG

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
R	B1	US-6,277,830 B1	08/21/2001	A. Ganguly, et al	
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
R	B2	WO 01/46212 A1	06/28/2001	ICN Pharmaceuticals, Inc.		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
R	B3	Ramasamy, K.S., et al, "Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity", J. Med. Chem (2000), pp 1019-1028, Vol. 43	

Examiner  
SignatureDate  
Considered

8-2-06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Doc. #125957v1